Reversal of rocuronium-induced neuromuscular blockade by sugammadex in patients undergoing kidney transplantation: Pharmacokinetics, efficacy, and safety analyses
Authors' conclusion
The significant differences in the pharmacokinetics of sugammadex between the patients undergoing kidney transplantation and healthy controls were observed.
Study context
- Population
- Patients with end-stage renal disease undergoing kidney transplantation and healthy controls, given sugammadex 2 mg·kg-1 at reappearance of TOF second twitch for rocuronium NMB reversalPK data from 30
- Participants
- 17 vs 17
- Comparison
- Sugammadex 2 mg·kg-1 in end-stage renal failure vs healthy controls
- Renal failuren = 17
- Controlsn = 17reference
- Outcome
- Pharmacokinetics of sugammadex
Methodological detailsnon-compartmental analysis
- Non-compartmental analysis
Main finding
As reported in the abstract
Elimination half-life of sugammadex
P < 0.001
Further findings
Plasma clearance of sugammadex
P < 0.001
Recovery of TOFR ≥ 0.9
- Similar between the two groups
Safety
- No sugammadex-related serious adverse events
Original publication
Reversal of rocuronium-induced neuromuscular blockade by sugammadex in patients undergoing kidney transplantation: Pharmacokinetics, efficacy, and safety analyses. J Clin Anesth. Published 11 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →